Covidien plc, a prominent player in the global healthcare industry, is headquartered in Ireland (IE) and operates extensively across North America, Europe, and Asia. Founded in 2000, the company has established itself as a leader in medical devices, pharmaceuticals, and surgical solutions, focusing on areas such as respiratory care, vascular therapies, and surgical instruments. Covidien is renowned for its innovative products, including advanced wound care solutions and minimally invasive surgical technologies, which enhance patient outcomes and streamline healthcare processes. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position and expanded its product portfolio. With a commitment to quality and innovation, Covidien plc continues to be a trusted name in the healthcare sector, recognised for its contributions to improving patient care worldwide.
How does Covidien plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Covidien plc's score of 46 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Covidien plc, headquartered in Ireland (IE), currently does not have specific carbon emissions data available for recent years. The company is a merged entity and inherits its climate commitments and emissions data from its parent organisation, Medtronic plc. As part of its climate strategy, Medtronic plc has set science-based targets (SBTi) aimed at reducing emissions across its operations. However, specific reduction targets or achievements for Covidien plc are not detailed in the available information. Covidien's climate initiatives are aligned with industry standards, reflecting a commitment to sustainability and carbon footprint reduction, although precise figures and targets are not disclosed. The absence of direct emissions data suggests that the company is still in the process of establishing its own metrics and goals, relying on the broader commitments of Medtronic plc. Overall, while Covidien plc is part of a larger corporate family with established climate initiatives, specific emissions data and reduction targets for the company itself remain unspecified.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 74,992,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 
| Scope 2 | 269,008,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | - | 
Covidien plc's Scope 3 emissions, which increased by 48% last year and increased by approximately 48% since 2021, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 55% of total emissions under the GHG Protocol, with "Downstream Transportation & Distribution" being the largest emissions source at 47% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Covidien plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.